Analytical validation of Aspyre Clinical Test for Lung (Blood): A multiplexed PCR and pyrophosphorolysis-based assay for detecting actionable NSCLC variants in plasma cfDNA and cfRNA
We present validation studies of Aspyre Clinical Test for Lung (Blood) using contrived and clinical samples. The technology is simple and fast, yet highly sensitive, specific, robust and reproducible with a turnaround time of two days. Aspyre Clinical Test for Lung (Blood) facilitates access to cost-effective, rapid, actionable molecular profiling of plasma for patients with NSCLC.
Authors
- Sam Abujudeh (ORCID: https://orcid.org/0000-0002-1127-4299)
- Justyna M Mordaka
- Barnaby W Balmforth (ORCID: https://orcid.org/0000-0002-3965-092X)
- Ryan Evans (ORCID: https://orcid.org/0009-0005-6289-5107)
- Alessandro Tomassini (ORCID: https://orcid.org/0000-0001-5645-6910)
- Julia N. Brown (ORCID: https://orcid.org/0000-0003-1912-0961)
- Rebecca N Palmer
- Wendy J. Levin
- Iyelola Turner
- Alejandra Collazos
- Magdalena Stolarek-Januszkiewicz
- Katherine Elizabeth Knudsen
- Ana-Luisa Silva
- Christina Xyrafaki
- Simonetta Andreazza (ORCID: https://orcid.org/0000-0001-8816-4955)
- Kelly R. Pitts
- Candace King
- Eleanor R. Gray (ORCID: https://orcid.org/0000-0002-6515-839X)
- Kristine von Bargen
- Shari Brown
- Elizabeth Gillon-Zhang
- Cory Kiser
- Amanda Green
- Chau Ha Ho
- Dilyara Nugent
- Jeffrey P. Gregg
- Jinsy Jose
- Mary Beth Rossi
- Prarthna Barot
- James Alexander Schaffernoth
Institutions
- North Carolina Institute of Medicine (US)
- Fidelity Biosciences (United States) (US)
Publication Details
- Journal
- The Journal of Liquid Biopsy
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1016/j.jlb.2025.100298
- Citations
- 2
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 1.87
Funders
- National Institute of General Medical Sciences